title: Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil--an area of Leishmania (V.) braziliensis transmission.
abstract: BACKGROUND
  The drug of choice for leishmaniasis is pentavalent antimony and different regimens are under continuous evaluation. The ideal therapy should be simple, effective, and with no or minor side-effects. In this paper we have studied the efficacy of intralesionally applied antimony in New World cutaneous leishmaniasis.
  
  
  METHODS
  Seventy-four patients from Rio de Janeiro state, Brazil, and presenting with single ulcerative cutaneous lesions mainly located on the trunk or extremities were enrolled in the study. The drug employed was N-methyl glucamine (425 mg of Sbv in each 5 ml ampoule). Each lesion was infiltrated with the drug at the four cardinal points in order to achieve complete blanching.
  
  
  RESULTS
  Of the 74 patients, 59 (80%) were healed after a 12-week interval. Extensive follow-up (up to 10 years) disclosed no relapses or the development of mucosal lesions.
  
  
  CONCLUSIONS
  The aim of therapy in New World cutaneous leishmaniasis is the healing of the cutaneous lesion and the prevention of late mucosal damage. Both conditions were achieved with the treatment employed with no side-effects and a considerable decrease in costs. In addition, the method is easy to apply in the field.
authors.affiliation: Hospital Evandro Chagas, Fundação Oswaldo Cruz, Brazil.
authors.forename: M P
authors.initials: MP
authors.lastname: Oliveira-Neto
authors.forename: A
authors.initials: A
authors.lastname: Schubach
authors.forename: M
authors.initials: M
authors.lastname: Mattos
authors.forename: S C
authors.initials: SC
authors.lastname: da Costa
authors.forename: C
authors.initials: C
authors.lastname: Pirmez
mesh_terms: D000328:Adult; D000818:Animals; D000965:Antimony / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D001938:Brazil; D003365:Costs and Cost Analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D007892:Leishmania braziliensis; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000635:transmission; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D012883:Skin Ulcer / Q000188:drug therapy / Q000469:parasitology; D016896:Treatment Outcome; D014945:Wound Healing
chemical_list: D000981:Antiprotozoal Agents; C006601:antimony-N-methylglucamine; D008536:Meglumine; D000965:Antimony